What Are the Biggest Challenges in Clinical Trial Patient Enrollment for Neurology Trials?

The pipeline of neurological drugs is considered one of the most exciting at the moment, ranging from disease-modifying agents for diseases such as Alzheimer's or Parkinson's to gene-based treatments for rare neuromuscular disorders. However, none of the advancements will ever benefit patients if there is no one participating in the trial itself. Clinical trial patient recruitment is among the most challenging aspects in the development of neurological drugs, and the obstacles preventing successful patient recruitment in neurological studies are unique enough to be discussed separately.

Overall, across all therapeutic areas, 80% of clinical trials fail to reach their expected enrollment milestones, while the failure to recruit the desired number of patients accounts for about 30% of Phase III study discontinuations. In the case of neurological studies, these numbers are even higher, due to the nature of the disease, which often affects memory, mobility, ability to communicate, or the capacity to make decisions, all of which help recruit patients in the first place.

This article breaks down the biggest challenges behind slow clinical trial enrollment in neurology, and what sponsors, sites, and patients can do about it in 2026.

Why Neurology Trials Are Uniquely Hard to Enroll

For cancer clinical trials, the selected patients are usually cognitively normal individuals with high motivation to seek treatment. Cardiology clinical trials usually have access to large databases of well-characterized patients. Neurology does not have both these advantages in many cases. Patient recruitment for clinical trials in the field has to factor in issues of cognitive impairment, physical impairment, caregiver dependence, and diseases with unpredictable progression while still trying to meet stringent patient eligibility requirements.

Here are the specific challenges driving slow clinical trial patient enrollment in neurology trials today.

1. Increasingly Complex Eligibility Criteria

The eligibility criteria for all therapeutic areas have become increasingly complex during the last two decades. Neurology clinical trials tend to be amongst the most complex studies, where there may even be over 60 criteria per trial, especially when testing drugs for treating neurodegenerative diseases and requiring a certain status of biomarkers, certain images, and disease staging.

Each criterion brings down the pool of potential patients. Patients suffering from early-stage Alzheimer's may be disqualified due to an unusual MRI image that is not related to the effects of the study drug, drug interactions, or the amyloid PET result that falls just short of the specified level. This is one of the greatest challenges in clinical trial patient enrollment because it reduces the pool of patients that would actually benefit from joining.

2. Cognitive and Communication Barriers to Informed Consent

Unlike other specialty areas, many neurology studies, especially those involving Alzheimer's disease, frontotemporal dementia, and more advanced cases of Parkinson's, involve recruiting subjects who may have diminished decision-making capabilities due to the disorder being tested. There is a genuine ethical and operational challenge when it comes to clinical trial patient enrollment, necessitating the need for capacity testing, legal representatives of the patients, and more time in the recruitment process compared to other therapeutic areas.

The sites must find a way of conducting the right consent procedures while at the same time considering the practical fact that any added step on the path may lead to the loss of the potential subject.

3. Caregiver Burden and Logistical Dependency

Many of the participants in neurological trials, particularly those in dementia, ALS, and severe multiple sclerosis studies, need a caregiver to transport them to their appointments, to take care of their medication, and attend the study visits. The dependence of the patient on his or her caregiver makes the process of recruiting the patient into the trial a two-perspective process instead of a single-perspective process. If the caregiver cannot dedicate themselves to travel, taking off from work, and the psychological impact that comes along with participating in multi-year studies, the participant will not be able to join the study even if he or she is eligible.

This is among the major factors that have made decentralized and hybrid trials increasingly critical in neurology recruitment over the past few years.

4. Low Public Awareness of Available Trials

However, awareness will remain one of the most fundamental barriers to overcome in any type of clinical research. It has been documented that less than 1 out of every 10 U.S. citizens claims full awareness of what participation in a clinical trial entails, while close to half of them state that they know nothing at all about it. The situation gets even worse when we look at neurology; patients and families become entangled in the process of a new diagnosis, with the need for specialist consultations, scans, and drug trials, but not once do they receive information about the trial conducted in their area.

It is one of the major factors that leads to the question of how to enroll in a clinical trial only after it is mentioned by someone else, like a friend or a support group.

5. Geographic Access and Site Concentration

Neurology studies that require a high level of specialty, especially in rare neurological disorders, frequently occur in only a few centers with specialized equipment and labs where the protocol can be executed successfully. This situation excludes a large region from having access to such a study center, thus leaving rural residents and those with no means of transportation at a disadvantage.

However, as more sponsors realize the importance of enhancing clinical trial patient enrollment, they try to establish hybrid networks including both an academic center and community neurology offices.

6. Underrepresentation of Diverse Patient Populations

The underrepresentation of women and various ethnic groups is a persistent issue in neurology clinical trials, including neurotrauma, stroke, and neurodegeneration trials. However, apart from being an equity issue, this issue also impacts the generalizability of the clinical trials' results since these trials cannot be easily generalized when the drug reaches the marketplace due to the low representation of certain groups of people in these trials. Several regulatory initiatives have been undertaken, such as the inclusion of the FDA Diversity Action Plan into requirements, in order to address this issue.

7. High Screen Failure Rates

Due to the extensive nature of the criteria required for neurology trials, the rate of screen failures in this therapeutic area is generally higher than normal. Patients who are very keen on joining the trial but manage to clear the initial phone screen may end up failing the entire screening process if their imaging tests or laboratory results show that they do not satisfy the required criteria. The fact that each screen failure means a waste of both the patient’s time and emotions slows down the entire process of enrolling patients into the clinical trial. Sites that collect information on why patients fail screens may manage to revise pre-screen questions and eliminate disqualifying factors early.

8. Disease Progression Working Against the Study Timeline

Neurodegenerative conditions do not take a break while a potential subject waits to enter the study. The individual who has shown eligibility at the point of first assessment may advance beyond the stage of the disease that makes him or her eligible for the study by the time all the assessments have been done, especially in cases where there are long multistep assessment processes involved in the process. This creates a narrow enrollment window that adds real-time pressure to clinical trial patient enrollment, especially for early-stage intervention trials where the therapeutic window itself is part of the scientific rationale.

9. Placebo Aversion and Trial Design Concerns

Most neurology studies, especially for progressive and irreversible diseases, continue to need a placebo group to satisfy regulatory requirements of evidence. The prospect of being on a placebo regimen for one or two years can be a big disincentive for those undergoing a degenerative illness without the guarantee of any gain through participating in the study. This issue is a recurrent one in patients' and caregivers' opinions concerning the inclusion in clinical trials, and one of the reasons why adaptive study design and open-label extension strategies are gaining prominence.

How to Increase Enrollment in Clinical Trials for Neurology Studies

Given these overlapping barriers, sponsors and sites are turning to a mix of strategies to address how to increase enrollment in clinical trials for neurology-specific research:

• Streamline eligibility requirements as much as scientifically possible. All eligibility criteria should be evaluated in terms of how relevant they are to answering the key research question, because anything unnecessary will limit the size of the pool without improving the science.

• Develop decentralized and hybrid aspects of the trial design. In-home visits and remote cognitive testing will help mitigate the care-giving and transportation burden that excludes many otherwise-eligible patients from enrollment.

• Develop referral networks with community neurologists, not only centers. A referral network can extend the geographical reach of a trial, as well as uncover patients at an earlier stage of their disease trajectory.

• Invest in proactive education of newly diagnosed patients. Since awareness is one of the key reasons why patients don’t enroll in clinical trials, establishing a pathway to referral by a neurologist from day one increases the number of referrals significantly.

• Implement patient matching using artificial intelligence technology. Using natural language processing software to screen for trial participants in electronic medical records saves time compared to manually reviewing charts. NeuroDiscovery AI is one example of such a platform, which takes the process one step further for neurology-specific trials by comparing real-life patient information with the inclusion/exclusion criteria of the trial before even considering telephone screenings.

• Recruit for study purposes specifically among underrepresented groups. It is necessary to establish links with community health facilities, use culturally appropriate outreach material, and site selection based on disease demographic characteristics rather than local to research institution demographic characteristics.

• Decrease patient burden through adaptable scheduling. By combining several assessments into one visit and making scheduling more flexible according to caregivers’ availability, patients will not drop out during the screening process.

How to Enroll in a Clinical Trial as a Neurology Patient

For patients and families wondering how to enroll in a clinical trial, the process generally follows these steps:

1. Speak to your neurologist. Many neurologists are aware of the current trials being conducted for that particular condition, even if they do not necessarily say anything about this in an office visit.

2. Look into the clinical trial registries. The United States' main registry is the ClinicalTrials.gov site, which enables one to look for any trials according to specific diseases, locations, and recruitment phase.

3. Talk to advocacy groups for patients with that condition. Those who have groups such as Alzheimer's, Parkinson's, ALS, and Multiple Sclerosis will usually keep up-to-date information regarding these trials.

4. Get in touch with the research coordinator at the trial site. Most trials will start with a phone call screening, after which you may be asked for an interview to verify your qualifications according to imaging, tests, and cognition.

5. Read the informed consent document very carefully. Do not hesitate to ask all the necessary questions from the research team.

How Does NeuroDiscovery AI Assist with Patient Recruitment for Clinical Trials?

The recruitment process is often the greatest bottleneck faced by researchers working with neurological or psychiatric clinical trials: limited patient eligibility, difficult-to-reach populations such as elderly, cognitively impaired, or pediatric patients, and fragmented patient data in healthcare organizations usually prolong the recruitment process from 6 to 18 months. NeuroDiscovery AI was specifically designed to solve this problem in the field of neurology and psychiatry.

• Patient matching using AI technologies. Matches the real-world patient data (diagnoses, biomarkers, comorbidities, disease progression) against eligibility criteria to find high-quality patients.
• Automatic pre-screening. Verifies patient eligibility before screening, reducing screen failures, delays, and expenses in the recruitment process.
• In-clinic recruitment. Finds eligible patients via a network of practicing neurologists who have access to those patients already undergoing treatment rather than recruiting them via the Internet.

Designed for complex neurological diseases. Particularly suitable for Alzheimer's disease, Parkinson's disease, multiple sclerosis, major depressive disorder, and others.

Final Thoughts

The solution to the problems faced by clinical trials in neurology when it comes to patient recruitment is not a simple task; it needs to solve issues concerning eligibility criteria, caregivers, geographical accessibility, awareness, and representation altogether. All of the aforementioned obstacles work together, making improvements in patient recruitment for clinical trials difficult, but not impossible to achieve through a combination of protocol development, site selection, and patient engagement efforts. In 2026, when many disease-modifying medications will be moving down the pipeline in neurology, it is the sponsors and sites that view patient recruitment as a design issue from the beginning of their efforts who will get their drugs to patients. As the technology of artificial intelligence becomes more entrenched in clinical trials, tools like NeuroDiscovery AI will assist sponsors and trial sites in identifying patients and matching them to trials using efficient analysis of clinical data.

FAQs

1. Why is clinical trial patient enrollment slower in neurology than in other specialties?

Neurology trials often involve cognitive impairment affecting consent capacity, caregiver dependency for logistics, narrow disease-stage windows, and unusually detailed eligibility criteria, all of which combine to make recruitment more complex than in many other therapeutic areas.

2. What is the biggest single barrier to clinical trial enrollment in neurology?

Awareness and eligibility complexity are consistently cited as the two largest barriers, though caregiver burden and geographic access to specialized sites are close behind for degenerative conditions.

3. How can sponsors realistically increase enrollment in clinical trials for rare neurological diseases?

Combining decentralized trial elements, community-based referral networks, and AI-assisted patient matching tends to produce the most measurable improvement, since these approaches directly target the awareness and access barriers driving low enrollment.

4. How do I find out if I'm eligible for a neurology clinical trial?

The most reliable path is asking your treating neurologist, searching ClinicalTrials.gov by your specific diagnosis, or contacting a condition-specific advocacy organization that maintains trial-matching resources.

5. Can decentralized clinical trials improve neurology patient enrollment?

Yes. Using trial models that use telemedicine and other forms of remote testing, monitoring, and data will ease the travel problem, increase access and patient enrollment, especially for those who have mobility problems or live far away from the specialized trial centers.